Skip to Main Content

Author Details

Felix Y Feng
UCSF Medical Center-Mount Zion
1997
458
83
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36710205Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.Eur Urol2024
37558543Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.Eur Urol Oncol2024
37507248Multi-institutional Development and External Validation of a Machine Learning Model for the Prediction of Distant Metastasis in Patients Treated by Salvage Radiotherapy for Biochemical Failure After Radical Prostatectomy.Eur Urol Focus2024
37423774The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.Eur Urol Oncol2024
37442672Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.Eur Urol Oncol2024
37474400Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes.Eur Urol Oncol2024
36351060Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.Cancer Res2023
37758702Author Correction: Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer.Nat Commun2023
37636316Co-evolution of <i>AR</i> gene copy number and structural complexity in endocrine therapy resistant prostate cancer.NAR Cancer2023
37714137Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA.Cell2023
37639648Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.J Clin Oncol2023
37393115Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies.Eur Urol2023
37289025The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.Cancer Res2023
37279434Reply to V. Nardone et al.J Clin Oncol2023
37173210Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.Eur Urol2023
37071498Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial.Clin Cancer Res2023
37137444Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.Int J Radiat Oncol Biol Phys2023
37003085Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.Eur J Cancer2023
36966268Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern era.Prostate Cancer Prostatic Dis2023
37398273Integrative identification of non-coding regulatory regions driving metastatic prostate cancer.bioRxiv2023
37331778Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation Oncology.Semin Radiat Oncol2023
37296155Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer.Nat Commun2023
37164128Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.Ann Oncol2023
37031196Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning.Nat Commun2023
37330052Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.Ann Oncol2023
36857638Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death.J Clin Oncol2023
36821396Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.JCI Insight2023
36749655DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations.Cancer Res2023
36780474New staging systems in nonmetastatic prostate cancer.Clin Adv Hematol Oncol2023
36648492Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer.Clin Cancer Res2023
36579470Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126.Cancer2023
36435709Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.Urol Oncol2023
36870853Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography.Eur Urol Oncol2023
36868922Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer.Eur Urol Oncol2023
36503624Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiation Therapy.Pract Radiat Oncol2023
36798177Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.Res Sq2023
36599119Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer.J Clin Oncol2023
36494221Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.Eur Urol2023
36596347Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials.Int J Radiat Oncol Biol Phys2023
36179990External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.Int J Radiat Oncol Biol Phys2023
36367998Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.J Clin Oncol2023
36269935Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.J Clin Oncol2023
33303244Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer.Eur Urol2022
35847550Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial.Adv Radiat Oncol2022
35509021Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.Clin Epigenetics2022
35737923Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.J Clin Oncol2022
35675855The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521.Int J Radiat Oncol Biol Phys2022
35440417Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].Eur Urol2022
35704598Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting.Sci Transl Med2022
35469702High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.Eur Urol2022
  • 1 - 50 of 458

Recommended Authors

Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 41
Christianne Hoey
Evaluative Clinical Sciences, Sunnybrook Research Institute
Career Start Year 2017
Number of shared co-authors 16
Natalie Kurganovs
Australian Prostate Cancer Research Centre Epworth
Career Start Year 2015
Number of shared co-authors 23
Stephanie A Wankowicz
University of California San Francisco
Career Start Year 2014
Number of shared co-authors 49
Joshua Armenia
Oncology R&D
Career Start Year 2013
Number of shared co-authors 58
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 8
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 48
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 22
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 47
John Thoms
Memorial University
Career Start Year 2008
Number of shared co-authors 20
Verena Sailer
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 39
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 34
Alastair D Lamb
University of Oxford
Career Start Year 2007
Number of shared co-authors 45
Aruz Mesci
Juravinski Cancer Centre
Career Start Year 2006
Number of shared co-authors 6
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 15
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 18
Jonathan L Wright
University of Washington Medical Center
Career Start Year 2005
Number of shared co-authors 52
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 44
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 32
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 53
Gregory R Pond
Juravinski Hospital and Cancer Centre, Escarpment Cancer Research Institute
Career Start Year 2001
Number of shared co-authors 33
Zhigang Zhang
Memorial Sloan Kettering Cancer Center
Career Start Year 2001
Number of shared co-authors 30
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 22
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 57
Vincent J Gnanapragasam
University of Cambridge
Career Start Year 1999
Number of shared co-authors 23
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 33
Melania Pintilie
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1993
Number of shared co-authors 56
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 47
Freddie C Hamdy
University of Oxford
Career Start Year 1987
Number of shared co-authors 64
Dominique Trudel
Institut du cancer de Montreal
Career Start Year 1985
Number of shared co-authors 42

Collaborators

Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 103
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Co-authored papers 68
Elai Davicioni
Veracyte Inc.
Co-authored papers 65
Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 53
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 53
Rohit Mehra
Michigan Center for Translational Pathology.
Co-authored papers 46
Todd M Morgan
University of Michigan ann arbor
Co-authored papers 45
Brandon A Mahal
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
Co-authored papers 44
William C Jackson
University of Michigan ann arbor
Co-authored papers 44
Eric J Small
University of California san francisco
Co-authored papers 43
Robert B Den
Thomas Jefferson University Hospital
Co-authored papers 39
Robert T Dess
University of Michigan ann arbor
Co-authored papers 38
Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers 38
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Co-authored papers 37
Edward M Schaeffer
Northwestern University Feinberg School of Medicine
Co-authored papers 35
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 31
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 30
Rahul Aggarwal
University of California San Francisco
Co-authored papers 30
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Co-authored papers 30
Amar U Kishan
University of California los angeles
Co-authored papers 28
David A Quigley
University of California-San Francisco
Co-authored papers 27
Ashley E Ross
Northwestern University
Co-authored papers 26
Xuhong Cao
Michigan Center for Translational Pathology.
Co-authored papers 25
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 25
Martin E Gleave
University of British Columbia
Co-authored papers 25
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 23
Martin Sj??str??m
University of California-San Francisco
Co-authored papers 22
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 22
Jeff M Michalski
Washington University School of Medicine
Co-authored papers 21
Thomas M Pisansky
Mayo Clinic
Co-authored papers 21
Release 1.2